ACBD3 inhibitors belong to a distinctive class of chemical compounds designed to selectively target and modulate the function of the ACBD3 protein. ACBD3, also known as Acyl-CoA Binding Domain-containing 3, is a vital cellular protein involved in lipid metabolism and intracellular vesicle transport. The chemical class of ACBD3 inhibitors is characterized by its ability to interfere with the normal activity of ACBD3, thereby influencing cellular processes that rely on this protein's function.
Structurally, ACBD3 inhibitors often possess specific chemical moieties that enable them to bind to the active site or allosteric pockets of the ACBD3 protein. This binding interaction disrupts the natural functioning of ACBD3, leading to alterations in lipid trafficking, membrane organization, and cellular signaling pathways. The design of these inhibitors is rooted in a profound understanding of the structural and biochemical properties of ACBD3, allowing for the development of compounds with high selectivity and potency. Researchers aim to leverage these inhibitors as powerful tools for investigating the physiological roles of ACBD3 in cellular processes, shedding light on the intricate mechanisms underlying lipid metabolism and vesicle transport within the cell.The exploration of ACBD3 inhibitors represents a significant stride in deciphering the intricacies of cellular biology, offering researchers the means to dissect the molecular underpinnings of lipid-related pathways. By selectively inhibiting ACBD3, these compounds provide a valuable platform for unraveling the complex interplay between lipid metabolism and cellular homeostasis, paving the way for a more comprehensive understanding of fundamental cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the Golgi structure by inhibiting ADP-ribosylation factor (ARF), a small GTPase that regulates vesicle formation, which can indirectly affect ACBD3. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A specifically targets Golgi brefeldin A resistant guanine nucleotide exchange factor 1 (GBF1), which can indirectly disrupt functions associated with ACBD3. | ||||||
Tyrphostin AG 1478 | 175178-82-2 | sc-200613 sc-200613A | 5 mg 25 mg | $96.00 $421.00 | 16 | |
AG1478 is an EGFR tyrosine kinase inhibitor that can modulate the EGFR signaling pathway and potentially influence Golgi function and indirectly ACBD3. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore inhibits dynamin, which is crucial for vesicle scission, thereby potentially influencing vesicular traffic related to ACBD3 functions. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubules, which are essential for Golgi organization and vesicular trafficking, thereby indirectly affecting ACBD3. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D disrupts actin filaments, which can alter the cytoskeleton and potentially affect vesicular transport and ACBD3-associated functions. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, which can affect protein folding and trafficking in the ER and Golgi, indirectly influencing ACBD3. | ||||||
Exo2 | 304684-77-3 | sc-215011 sc-215011A | 5 mg 25 mg | $89.00 $288.00 | 1 | |
Exo2 ADP-ribosylates and inactivates Rho GTPases, affecting cytoskeletal organization and potentially Golgi function related to ACBD3. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a Cdc42 inhibitor, potentially affecting cytoskeletal dynamics and indirectly influencing ACBD3's role in vesicular trafficking. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Latrunculin B binds to actin monomers and can disrupt actin polymerization, indirectly affecting the cytoskeleton and ACBD3-associated processes. | ||||||